KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Operating Expenses: 2020-2025

Historic Other Operating Expenses for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to $41.3 million.

  • Esperion Therapeutics' Other Operating Expenses rose 138.86% to $41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year increase of 133.36%. This contributed to the annual value of $68.6 million for FY2024, which is 58.55% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Other Operating Expenses is $41.3 million, which was up 44.66% from $28.5 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Other Operating Expenses peaked at $41.3 million during Q3 2025, and registered a low of $1.8 million during Q1 2021.
  • Moreover, its 3-year median value for Other Operating Expenses was $15.6 million (2024), whereas its average is $19.4 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Other Operating Expenses skyrocketed by 5,654.84% in 2021, and later declined by 26.05% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Other Operating Expenses (Quarterly) stood at $5.1 million in 2021, then fell by 18.03% to $4.2 million in 2022, then soared by 175.29% to $11.5 million in 2023, then soared by 123.81% to $25.6 million in 2024, then spiked by 138.86% to $41.3 million in 2025.
  • Its Other Operating Expenses was $41.3 million in Q3 2025, compared to $28.5 million in Q2 2025 and $31.5 million in Q1 2025.